Sarm1 enzyme activity inhibitor and application thereof
US-2024368168-A1 · Nov 7, 2024 · US
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
US9937169B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9937169-B2 |
| Application number | US-201414254017-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 16, 2014 |
| Priority date | Apr 17, 2013 |
| Publication date | Apr 10, 2018 |
| Grant date | Apr 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating castration-resistant prostate cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound in combination with an effective amount of MDV3100 to a patient having castration-resistant prostate cancer, wherein the Dihydropyrazino-Pyrazine Compound is a compound having the structure: or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof. 2. The method of claim 1 , wherein the castration-resistant prostate cancer is a relapsed or refractory castration-resistant prostate cancer. 3. The method of claim 1 , wherein the castration-resistant prostate cancer is an E-twenty six (ETS) overexpressing castration-resistant prostate cancer. 4. The method of claim 1 , wherein the castration-resistant prostate cancer is metastatic castration-resistant prostate cancer.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for metastasis · CPC title
Antineoplastic agents · CPC title
of the prostate · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9937169B2 cover?
- Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
- Who is the assignee on this patent?
- Signal Pharm Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4985. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).